Michael Barbella, Managing Editor08.13.22
Products and personnel news peaked page views this past week on the ODT website.
Leading the charge was word that NuVasive Chief Commercial Officer Massimo Calafiore is resigning from the company on Aug. 31 to become the CEO of a privately-held orthopedic technology company. Upon his resignation, Calafiore’s responsibilities will be reallocated among management while the company aligns commercial structure to long-term strategy.
Product news of interest to cybervisitors came from AxioMed, Exactech, and MicroPort. AxioMed submitted the Module III documents needed to get U.S. Food and Drug Administration (FDA) approval to market its lumbar viscoelastic disc replacement in the United States. AxioMed stands as the only viscoelastic disc replacement to ever complete a U.S. IDE Clinical study. The clinical data is strong with greater than five-year followup data showing no reported device related failures, no revisions and rare cases of heterotopic bone formation. Outside the Untied States, the cervical and lumbar discs have been used clinically in Australia, Europe and the Caribbean.
Exactech, meanwhile, this week debuted shoulder sports medicine, arthroscopy, and arthroplasty exacCoach message streams to connect surgeons and patients throughout the care journey. The exacCoach tech is powered by the company’s Active Intelligence platform. Surgeons can use it to virtually coach patients via automated text messages from surgical prep through rehab. Detailed and encouraging information personalized to each surgeons and practice is designed to boost patient satisfaction. The technology helps properly inform patients, increase office efficiencies, reduce time spent undergoing patient management, and allow new patient visits, enrollments, and additional surgeries.
Finally, MicroPort Navibot received FDA 510(K) clearance for the SkyWalker System, its first robot-assisted platform for orthopedic applications. SkyWalker will initially offer a robotically assisted total knee replacement solution that is compatible with the Evolution Medial-Pivot total knee system. Designed based on clinical needs, MicroPort NaviBot has built a full technology research facility that has medical industry design capability, and benefits from core technological advantages of having a self-developed, high-dexterity, and lightweight mechanical arm combined with intelligent planning and navigation algorithms. SkyWalker has the technical advantages of precise operation and efficient coordination, while prioritizing safety.
Leading the charge was word that NuVasive Chief Commercial Officer Massimo Calafiore is resigning from the company on Aug. 31 to become the CEO of a privately-held orthopedic technology company. Upon his resignation, Calafiore’s responsibilities will be reallocated among management while the company aligns commercial structure to long-term strategy.
Product news of interest to cybervisitors came from AxioMed, Exactech, and MicroPort. AxioMed submitted the Module III documents needed to get U.S. Food and Drug Administration (FDA) approval to market its lumbar viscoelastic disc replacement in the United States. AxioMed stands as the only viscoelastic disc replacement to ever complete a U.S. IDE Clinical study. The clinical data is strong with greater than five-year followup data showing no reported device related failures, no revisions and rare cases of heterotopic bone formation. Outside the Untied States, the cervical and lumbar discs have been used clinically in Australia, Europe and the Caribbean.
Exactech, meanwhile, this week debuted shoulder sports medicine, arthroscopy, and arthroplasty exacCoach message streams to connect surgeons and patients throughout the care journey. The exacCoach tech is powered by the company’s Active Intelligence platform. Surgeons can use it to virtually coach patients via automated text messages from surgical prep through rehab. Detailed and encouraging information personalized to each surgeons and practice is designed to boost patient satisfaction. The technology helps properly inform patients, increase office efficiencies, reduce time spent undergoing patient management, and allow new patient visits, enrollments, and additional surgeries.
Finally, MicroPort Navibot received FDA 510(K) clearance for the SkyWalker System, its first robot-assisted platform for orthopedic applications. SkyWalker will initially offer a robotically assisted total knee replacement solution that is compatible with the Evolution Medial-Pivot total knee system. Designed based on clinical needs, MicroPort NaviBot has built a full technology research facility that has medical industry design capability, and benefits from core technological advantages of having a self-developed, high-dexterity, and lightweight mechanical arm combined with intelligent planning and navigation algorithms. SkyWalker has the technical advantages of precise operation and efficient coordination, while prioritizing safety.